Gilead, Seattle
Gilead lays off 72 workers in Seattle, plans to shutter R&D support site
Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh its cell therapy subsidiary. | Gilead will lay off 72 staffers in Seattle, the company confirmed Thursday.
COVID drugmaker to close Seattle office, laying off 72 workers
The Washington State Employment Security Department said in the filing that 72 employees will be laid off on Jan. 17. A Gilead spokesperson said in an emailed statement that some teams will be moved to other offices outside of Seattle.
Biotech giant Gilead Sciences to close its Seattle office, lay off employees
Global biopharmaceutical company Gilead Sciences Inc. (Nasdaq: GILD) is closing its office in Seattle and laying off 72 employees, according to a Washington state Worker Adjustment and Retraining Notification filed on Wednesday.
Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.
Wolfe Research initiated coverage of Gilead (GILD) with an Outperform rating and $110 price target Gilead’s bread and butter has been ...
Hosted on MSN18h
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should KnowGilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Zacks.com on MSN18h
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a BetWhen deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often ...
Wolfe Research initiated coverage of Gilead (GILD) with an Outperform rating and $110 price target Published first on TheFly – the ...
Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...
(This story was updated to accurately reflect the most current information.) OBETZ — Mount Gilead left nothing to chance ...
(RTTNews) - Gilead Sciences Inc. (GILD) announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering, consisting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback